Welcome to our dedicated page for Evogene news (Ticker: EVGN), a resource for investors and traders seeking the latest updates and insights on Evogene stock.
Evogene Ltd. (EVGN) is a computational biology and chemistry company that regularly publishes news about its AI‑driven platforms, collaborations and corporate developments. The EVGN news feed on Stock Titan aggregates company press releases and related coverage so readers can follow how Evogene applies big data and artificial intelligence to life‑science product discovery in pharmaceuticals and agriculture.
Recent announcements highlight Evogene’s focus on ChemPass AI, its generative AI tech‑engine for small‑molecule design and optimization. News items include the completion of a generative AI foundation model for small‑molecule design developed with Google Cloud, as well as updates on how ChemPass AI is being positioned as the core engine for the company’s pharma and agricultural activities.
Evogene’s news also covers scientific collaborations, such as agreements with Unravel Biosciences to design small‑molecule therapeutics for demyelinating diseases and with a Tel Aviv University research group to develop small molecules targeting metabolite self‑assembly in metabolic diseases. In agriculture, readers can find updates related to subsidiaries like Casterra Ag, including partnerships to advance mechanized castor farming for bio‑based industries.
In addition, the EVGN news stream features financial and corporate communications, including quarterly results, conference call schedules, investor conference presentations, restructuring steps and transactions such as the sale of most of Lavie Bio’s activity and the MicroBoost AI for Ag platform to ICL. Investors and observers can use this page to monitor how Evogene’s strategy, partnerships and technology platforms evolve over time.
Biomica, a biopharmaceutical company and subsidiary of Evogene (NASDAQ: EVGN), has entered a collaboration with Sheba Medical Center to research Inflammatory Bowel Disease (IBD). This partnership aims to explore microbiome profiles in IBD patients to better understand the condition and develop innovative therapies. The global IBD treatment market was valued at USD 19.2 billion in 2020. Biomica plans to scale up and produce initial clinical batches of its product candidate, BMC333, following positive pre-clinical results.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Jefferies Virtual Synthetic Biology Week from March 21-25, 2022. Chief Product Officer, Dr. Nir Arbel, will engage in a fireside chat on March 23, 2022, at 10 am ET and will be available for one-on-one meetings with investors on March 24, 2022. Evogene aims to transform life-science product development through its innovative technological engines: MicroBoost AI, ChemPass AI, and GeneRator AI. These engines focus on microbiome therapeutics, medical cannabis, ag-chemicals, and ag-biologicals.
Evogene Ltd. (NASDAQ: EVGN) reported its financial results for Q4 and full year 2021, showing an operating loss of $31 million, up from $24.8 million in 2020. The company maintains a solid cash position of approximately $54 million, aiding its subsidiaries in product development. Key achievements include Biomica's clearance for a phase I immuno-oncology study and Canonic's commercial sales of cannabis products. Looking ahead, Evogene targets 2022 milestones such as launching new products and expanding R&D activities.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the upcoming World Agri-Tech Innovation Summit on March 22-23, 2022, in San Francisco. This summit has established itself as a pivotal event for the global agtech ecosystem, bringing together growers, agribusiness leaders, technology pioneers, and investors. Key executives from Evogene, including CEO Ofer Haviv and other senior management from its subsidiaries, will be present to explore partnerships and insights. Evogene leverages cutting-edge computational biology to innovate in various life-science industries.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the 34th Annual ROTH Conference in Dana Point, California, from March 13-15, 2022. CEO Ofer Haviv will host a live fireside chat on March 15 at 12pm PT, along with one-on-one meetings with investors. The conference includes various presentations and panels, attracting institutional investors and analysts. Evogene's innovative technologies, such as MicroBoost AI and GeneRator AI, are focused on life-science product development.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the appointment of Professor Itamar Grotto to its Board of Directors. Grotto, formerly of the Israeli Ministry of Health, brings extensive expertise in medical cannabis reform. His role aims to bolster Canonic's mission of developing medical cannabis products targeting specific medical indications. Grotto believes in the potential of Canonic to enhance patient care and expressed eagerness to contribute to the company's growth. CEO Arnon Heyman welcomed Grotto, emphasizing his valuable experience for advancing Canonic's strategic goals.
Evogene Ltd. (NASDAQ: EVGN) is set to release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. Following the announcement, management will host a conference call at 09:00 AM Eastern time to discuss these results. The call can be accessed via phone or live webcast on the company's website. Evogene leverages advanced computational biology technologies to enhance life-science product development across various sectors including therapeutics and ag-chemicals.
Evogene Ltd. (NASDAQ-GM: EVGN) will present an overview at the Aegis Capital Corp. Virtual Conference from February 23 to 25, 2022. The presentation is set for February 25 at 9:00 AM EST. Interested participants can access the presentation upon request to Aegis or view the slide deck on Evogene's website. Evogene is a computational biology company aiming to innovate product development in life sciences, using its Computational Predictive Biology platform.
Canonic Ltd., a subsidiary of Evogene Ltd. (NASDAQ: EVGN), announced the shipment of its first batch of cannabis varieties to Portugal after receiving export approval from the Israeli Ministry of Health and Ministry of Agriculture. This shipment is part of Canonic's preparations for a planned commercial launch in Europe in 2023, focusing on developing medical cannabis products using its Computational Predictive Biology platform. The shipped cannabis varieties will undergo lab testing and regulatory examination to comply with European regulations.
Evogene Ltd. (NASDAQ: EVGN) announced its participation in the Edison Group's Global Healthcare Open House Event from January 25-27, 2022. The event will take place virtually, and Evogene's presentation will be available on demand starting at 7 AM ET on January 27. Attendees can also register for 1x1 meetings with the company. Evogene utilizes its Computational Predictive Biology platform to advance product pipelines in various life-science sectors, including human health and agriculture.
FAQ
What is the current stock price of Evogene (EVGN)?
What is the market cap of Evogene (EVGN)?
